Hasenfuss G, Pieske B, Kretschmann B, Holubarsch C, Alpert N R, Just H
Medizinische Klinik III, Universitat Freiburg, Germany.
J Cardiovasc Pharmacol. 1995;26 Suppl 1:S45-51.
Calcium sensitizers may influence myocardial energetics by their action on calcium turnover and on crossbridge behavior. Using a myothermal method, the effects of the Ca2+ sensitizer EMD-53998 on calcium cycling, crossbridge behavior, and myocardial energy turnover were compared with the effects of an increase in extracellular calcium from 1.25 to 7.5 mM and with the effects of the catecholamine isoproterenol. All three inotropic interventions increased isometric force development in right ventricular rabbit papillary muscles. Relaxation time was decreased with isoproterenol, unchanged with high calcium, and increased with EMD 53998. Calcium cycling-related energy consumption, as measured by tension-independent heat, increased by 234% with high calcium, by 439% with isoproterenol, and by 77% with EMD 53998. In contrast to high calcium and isoproterenol, EMD 53998 increased economy of crossbridge cycling by increasing the force-time integral of the individual crossbridge cycle. The data indicate that EMD 53998 acts by phosphodiesterase inhibition and myofilament calcium sensitization. The latter effect is in part mediated by alteration of crossbridge behavior. Because of its effects on calcium cycling and crossbridge function myocardial energy turnover was reduced significantly with EMD 53998, whereas energy turnover was unchanged with high calcium and was increased with isoproterenol. The new calcium sensitizer levosimendan was investigated in isolated failing human myocardium. Levosimendan dose-dependently increased isometric tension. The inotropic effect was associated with increased rate of relaxation and reduced relaxation time. Measurements of intracellular calcium using the photoprotein aequorin suggest that levosimendan acts by increasing myofilament calcium sensitivity and by increasing cAMP due to phosphodiesterase inhibition. However, the contribution of the cAMP system to the action of levosimendan appears to be rather small. Therefore, the finding of a positive lusitropic effect of levosimendan may be consistent with the notion that levosimendan binds to troponin-C and increases calcium sensitivity only at high (systolic) intracellular calcium concentrations.
钙敏化剂可能通过其对钙周转和横桥行为的作用来影响心肌能量代谢。采用肌热法,将Ca2+敏化剂EMD - 53998对钙循环、横桥行为和心肌能量周转的影响,与细胞外钙浓度从1.25 mM增加到7.5 mM的影响以及儿茶酚胺异丙肾上腺素的影响进行了比较。所有这三种变力干预措施均增加了兔右心室乳头肌的等长力发展。异丙肾上腺素使舒张时间缩短,高钙时舒张时间不变,而EMD 53998使舒张时间延长。以与张力无关的热量衡量的与钙循环相关的能量消耗,高钙时增加234%,异丙肾上腺素时增加439%,EMD 53998时增加77%。与高钙和异丙肾上腺素不同,EMD 53998通过增加单个横桥循环的力 - 时间积分来提高横桥循环的经济性。数据表明,EMD 53998通过抑制磷酸二酯酶和使肌丝对钙敏化而起作用。后一种效应部分是由横桥行为的改变介导的。由于其对钙循环和横桥功能的影响,EMD 53998使心肌能量周转显著降低,而高钙时能量周转不变,异丙肾上腺素时能量周转增加。在离体的衰竭人心肌中对新型钙敏化剂左西孟旦进行了研究。左西孟旦剂量依赖性地增加等长张力。变力作用与舒张速率增加和舒张时间缩短有关。使用光蛋白水母发光蛋白测量细胞内钙表明,左西孟旦通过增加肌丝对钙的敏感性以及由于抑制磷酸二酯酶而增加环磷酸腺苷(cAMP)起作用。然而,cAMP系统对左西孟旦作用的贡献似乎相当小。因此,左西孟旦具有正性变松弛作用这一发现可能与左西孟旦仅在高(收缩期)细胞内钙浓度下与肌钙蛋白C结合并增加钙敏感性的观点一致。